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Lacticin 3147 is a lantibiotic with seven lanthionine
bridges across its two component peptides, Ltna
and Ltnb. Although it has been proposed that the
eponymous lanthionine and (b-methyl)lanthionine
(Lan and meLan) bridges present in lantibiotics
make an important contribution to protecting the
peptides from thermal or proteolytic degradation,
few studies have investigated this link. We have
generated a bank of bioengineered derivatives of
lacticin 3147, in which selected bridges were
removed or converted between Lan and meLan,
which were exposed to high temperature or proteo-
lytic enzymes. Although switching Lan and meLan
bridges has variable consequences, it was consis-
tently observed that an intact N-terminal lanthionine
bridge (Ring A) confers Ltna with enhanced resis-
tance to thermal and proteolytic degradation.
INTRODUCTION
Lantibiotics are a class of highly active antimicrobial peptides
active against many Gram-positive bacteria (Brumfitt et al.,
2002; Cotter et al., 2006; Galvin et al., 1999; Kruszewska et al.,
2004; Piper et al., 2009a; Ryan et al., 1996, 1999a). These
peptides undergo distinctive posttranslational modifications
that result in the formation of lanthionine and/or (b-methyl)lan-
thionine bridges (Lan or meLan). Lanthionines are internal ring
structures that result from the dehydration of serine and threo-
nine to dehydroalanine (Dha) and dehydrobutyrine (Dhb), which
then react with cysteine through a Michael-type addition, to
form Lan and meLan bridges (Chatterjee et al., 2005; Cotter
et al., 2005a; Pag and Sahl, 2002; Willey and van der Donk,
2007; Xie and van der Donk, 2004). There are extensive data
demonstrating the importance of these bridges in providing
lantibiotics with a biologically active conformation (Breukink
and de Kruijff, 1999; Breukink et al., 1999; Brotz et al., 1998;
Chatterjee et al., 2005). Numerous reviews focusing on these
peptides also propose that these rings contribute to resistance
to degradation by thermal stress or proteolytic enzymes.Chemistry & Biology 17, 1151–1However, to date, there exists relatively little supporting
evidence for this theory. Although a role for (me)Lan in thermal
stability was first mooted byHurst (1981) and has been reiterated
on a number of occasions, there exists no example of a direct
comparison between the thermotolerance of a peptide with
and without a (me)Lan bridge. Evidence for a role in protecting
against proteolytic degradation is much stronger in that a study
by Bierbaum et al. (1996) elegantly demonstrated that the
removal of a C-terminally located meLan or Lan structure from
the lantibiotic Pep5 enhanced the sensitivity of the peptide to
proteases, and, conversely, the introduction of a fourth bridge
(MeLan) in the same peptide increased stability when exposed
to chymotrypsin and Lys-C (Bierbaum et al., 1996). Further
indirect evidence of the importance of (me)Lan bridges in lantibi-
otic stability has been provided by demonstrating the beneficial
consequences of introducing such structures into non-lantibiotic
peptides. Replacement of a cysteine bridge in Sandostatin with
a lanthionine bridge improved the serum stability of the peptide
(Osapay et al., 1997), whereas the introduction of lanthionine
residues increased the bio-stability and bioavailability of
enkephalin (Rew et al., 2002) and angiotensin (Kluskens et al.,
2009) as well as the protease resistance of the peptide hormone
LHRH (Rink et al., 2010).
For this study we selected lacticin 3147, a two-peptide lantibi-
otic active through the synergistic activity of Ltna and Ltnb
(Figure 1). This lantibiotic was first isolated from Lactococcus
lactis subsp. lactis DPC3147 in 1995 (Ryan et al., 1996) and
exhibits broad-spectrum activity against a variety of Gram-posi-
tive targets (Field et al., 2008; Galvin et al., 1999; Piper et al.,
2009b; Rea et al., 2007) as a consequence of a dual ability to
inhibit peptidoglycan synthesis and form pores in target cell
membranes (both of which are dependent on the interaction of
the lantibiotic with the peptidoglycan precursor lipid II; Wiede-
mann et al. [2006]). Ltna is a globular peptide consisting of 30
amino acids, of which 11 are posttranslationally modified (Martin
et al., 2004). The structure of Ltna is very similar to that of the
a component of another two-peptide lantibiotic, haloduracin
(Cooper et al., 2008), and the single peptide lantibiotic, mersaci-
din (Chatterjee et al., 1992). Indeed, it is believed that all
members of the extended subgroup of mersacidin-like peptides
have a similar conformation (Lawton et al., 2007). In the case of
Ltna, this means that three serines are ultimately modified to
form two Lans (with two cysteines) and a D-alanine, whereas160, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1151
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Figure 1. Structures of the Lacticin 3147
Peptides Ltna and Ltnb
Lan (Ala-S-Ala) andmeLan (Abu-S-Ala) bridges are
indicated. See also Figure S1.
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Role of Lanthionines in Lacticin 3147four threonines are modified to become two meLans (with
another two cysteines) and two Dhbs (Cotter et al., 2005b;
Ryan et al., 1999b). Despite the generally conserved structure
of these peptides, the presence of a Lan (or meLan) generated
through the modification of two adjacent residues, as is the
case with Ring A at the N terminus of the peptide, remains
a rare feature across all lantibiotics and outside of Ltna (and
presumably the closely related C55a; Navaratna et al. [1998];
O’Connor et al. [2007]) has only been observed in mersacidin
(meLan). It is interesting to note that investigations with mersaci-
din have revealed that the corresponding Ring A folds back into
the lipid II binding pocket of this lantibiotic when in the presence
of membrane-mimicking DPC micelles but that the addition of
lipid II results in the reexposure of the lipid II binding site
(Hsu et al., 2003). Ring A is also unusual by virtue of the fact
that, in contrast to the vast majority of Lan/meLan bridges, the
cysteine contributing to the bridge is located downstream of its
serine partner (Martin et al., 2004). Ltna is representative of
a larger number of lantibiotic peptides (which includes the
related C55a, Hala, mersacidin, and actagardine peptides) in
which the N-terminal residue is involved in the formation of
a bridge structure. Notably, studieswith the haloduracin peptide,
Hala, revealed that disrupting the disulphide bridge present at its
N terminus resulted in additional N-terminal proteolysis (Cooper
et al., 2008). In contrast to Ltna, Ltnb is a linear cationic peptide.
It consists of 29 amino acids, of which 11 are posttranslationally
modified. Five threonines are modified (whereas three remain
unmodified) to form two meLan bridges (with two cysteines),
two Dhbs, and a 2-oxobutyrl group (arising from the deamination
of an N-terminal Dhb). All three serines are modified to generate
one lanthionine bridge (with one cysteine) and two D-alanines
(Martin et al., 2004).
Our knowledge to date of the importance of Lan and meLan
structures in lacticin 3147 has been generated through in vivo1152 Chemistry & Biology 17, 1151–1160, October 29, 2010 ª2010 Elsevier Ltd All rights resbioengineering studies (Cotter et al.,
2006; Field et al., 2007). Theseestablished
that in six instances when a (me)Lan
bridge is eliminated as a consequence of
changing one of the associated Ser, Thr,
or Cys residues (in most cases to an
alanine residue), the antimicrobial activity
was abolished. In contrast, manipulations
of Cys1 or Ser2 of Ltna, i.e., changes re-
sulting in the removal of Ring A, had
a more subtle impact on activity (Cotter
et al., 2006; Field et al., 2007). Indeed,
this represented only the fourth example
of an in vivo bioengineered (me)Lan in
which any antimicrobial activity was
retained following bridge disruption; the
other examples being mutacin II C27A
(Chen et al., 1998) and Pep5 C27A andC33A (Bierbaum et al., 1996). More recently, an in vitro-based
alanine mutagenesis strategy has also been employed to probe
the consequences of mutating cysteines involved in (me)Lan
formation in haloduracin (Hala, Halb) (Cooper et al., 2008).
In this instance, although the HalaC27A, C17A, and HalbC15A,
C20A, andC24Apeptidesall displayedgreatly reducedornoanti-
microbial activity, HalaC23A and HalbC5A retained a significant
degree of activity; in all instances these assays were carried out
in the presence of unmutated sister peptide (Cooper et al., 2008).
In this study we use the lacticin 3147 peptides, Ltna and Ltnb,
to carry out a systematic in vivo bioengineering-based investiga-
tion of the impact of the manipulation of Lan/meLan bridges on
antimicrobial activity. As a consequence of its tolerance to
change, Ring A of Ltna was the subject of greatest focus, and
the extent to which it can be manipulated was tested by adding
five additional derivatives to the existing collection of two Ring
A mutants. This included one peptide in which the existing Lan
bridge was replaced by a meLan. To assess whether such Lan-
meLan interconversion might be tolerated at other locations
within the two peptides, a further six bioengineered strains/
peptides, inwhich the remaining bridgeswere eachmanipulated,
were created. In addition to assessing the nature of the peptides
produced and quantifying the impact of these changes on
specific activity, this collection of bioengineered peptides was
also assessed to determine the consequences of these changes
and, thus, the role of (me)Lan structures,with respect to the resis-
tance of these peptides to proteases and thermal stress.
RESULTS
Design and Construction of Ltna Ring A and Bridge
Variants of Lacticin 3147
Alanine-scanning mutagenesis of lacticin 3147 revealed that
both residues contributing to Ring A of Ltna could be convertederved
Ltnα
mutant
Mass Da
(+ cyan) a Structure(s)
Activity
vs. L. lactis
Ltnα (µM)
vs. L. lactis
Plus β (nM)
vs. L. lactis
Plus β (nM)
vs. M. luteus
Wild type 6518.952.1)0+(5033
C1A 05215.2135.2>4.3723
S2A 00525265.2>7.7033
C1S 00525.2135.2>9.9823
S2C 052100525.2>)05+(7333
C1S/S2C
3306.3 (+25),
3323.4
>2.5
1250,
1250
2500,
2500
S2T 005200525.2>)0+(5.9133
C1A/S2A 052100525.2>1.5723
Figure 2. Ring A Mutants of Ltna
Mass of the bioengineered peptides, predicted
structures, and visual demonstration of antimicro-
bial activity of 50 ml bioengineered peptide when
combined with wild-type sister peptide (both at
2.5 mM concentrations) against L. lactis HP and
broth-based MIC determination of antimicrobial
activity against L. lactis HP and M. luteus. a,
mass difference following cyanylation is in
brackets; *, D-chiral center.
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Role of Lanthionines in Lacticin 3147to alanine without eliminating the antimicrobial activity of the
bioengineered strain (Cotter et al., 2006). As a consequence of
the unusual size, location, and tolerance to change of Ring A, it
became the focus of further investigation. More specifically,
five bioengineered peptides were designed: LtnaC1S, S2C,
S2T, and two double-mutants LtnaC1S-S2C and C1A-S2A.
The creation of LtnaS2T allowed us to assess the consequences
of replacing a Lan with a meLan bridge at this location, whereas
LtnaS2C could result in several outcomes, including two unmod-
ified cysteines at positions 1 and 2, the formation of a disulphide
bridge between the same two cysteines, or the possible forma-
tion of a meLan between either cysteine and the Dhb located
at position 3. There are also many possible consequences to
the creation of the LtnaC1S prepeptide, including the introduc-
tion of an N-terminal serine or 2-oxopropionate (2-OP) following
spontaneous deamination of an N-terminal Dha. The doubly
altered peptides had the potential to invert the Lan bridge at
the N terminus (LtnaC1S-S2C) or to create a peptide beginning
with Ala-Ala (LtnaC1A-S2A), which would act as a mimic of the
natural Lan (Ala-S-Ala), but without a thiol bridge and with an
altered chirality of the second a carbon.
Following the successful creation of all of these strains, initial
bioactivity based analyses revealed that in all cases antimicro-
bial activity against the lacticin 3147 sensitive indicator Lacto-
coccus lactis HP was retained (data not shown). Colony mass
spectrometry was performed to gain an insight into the nature
of the modifications occurring at the N termini of the bioengi-
neered peptides. In the case of LtnaC1S, a mass of 3289.9
daltons is consistent with the presence of an N-terminal 2-OP.
LtnaS2C has a mass of 3337 daltons, and cyanylation of this
peptide resulted in a 50 dalton increase in mass, consistent
with the presence of two unmodified cysteines (Figure 2). The
LtnaS2T peptide has a mass of 3319 daltons (Figure 2), which
is consistent with either a Cys-Dhb N terminus or an N-terminalChemistry & Biology 17, 1151–1160, October 29, 2010 ªbridge between the residues (in this
instance a meLan). Cyanylation was
again employed and revealed that no
free cysteines were present (Figure 2).
The C1A-S2A mutation results in the
replacement of the Lan bridge with two
alanines, whereas the C1S-S2C change
results in two peptides of mass 3306
and 3323 Da, consistent with the pres-
ence of an N-terminal 2-OP and serine,
respectively, and, thus, inversion of the
natural Lan bridge did not occur (Figure 2).
The first of the two C1S-S2C peptideswas subjected to cyanylation, which confirmed the presence of
an unmodified cysteine at position 2 (Figure 2).
Antimicrobial Activity of Ltna Ring A Variants
Agar-based assays using purified Ring A variant peptides
combined with native Ltnb revealed differences in antimicrobial
activity against L. lactis HP. Broth-based minimum inhibitory
concentration (MIC) studies were carried out to test the activity
of the peptides, both alone and in combination with equimolar
concentrations of Ltnb. All peptides were active, albeit at levels
lower than that of the wild-type equivalent, confirming the toler-
ance of Ring A to change. The MIC of all individual mutant
peptides was greater than 2.5 mM, but all peptides were active
at or below this concentration when combined with Ltnb
(Figure 2). Of these, LtnaC1A and LtnaC1S were most active
(MIC of 312.5 nM when combined with Ltnb) (Figure 2), whereas
LtnaS2Awas 60-fold less active than the wild-type. Interestingly,
those peptides that were created with the anticipation that their
N terminus would most resemble that of the wild-type peptide
were least active. The unsuccessful attempt to invert the Lan
bridge (C1S-S2C) resulted in peptides (with N-terminal 2-OP-
Cys and Ser-Cys sequences) that both had MICs of 1250 nM,
and the replacement of the original Lan bridgewith either MeLan,
Cys-Cys, or Ala-Ala all resulted in the corresponding peptides
having an MIC of 2.5 mM when combined with Ltnb (Figure 2).
MIC investigations, with equimolar concentrations of purified
Ltna and b peptides, were also carried out using a second target
strain, Micrococcus luteus DSM1790, to differentiate between
generalized and strain-specific impacts. Although all combina-
tions tested also exhibited antimicrobial activity against this
target, the wild-type combination was again the most active
(MIC 156 nM). The bioengineered peptides could be divided
into two categories. When combined with Ltnb, LtnaC1A,
LtnaS2C, and LtnaC1A/S2A had a MIC of 1250 nM, whereas2010 Elsevier Ltd All rights reserved 1153
Figure 3. Lan-meLan Interconversion of
Rings B–F
Mass of the bioengineered peptides, predicted
structures, and visual demonstration of antimicro-
bial activity of 50 ml bioengineered peptide when
combined with wild-type sister peptide (both at
2.5 mM concentrations) against L. lactis HP and
broth-based MIC determination of antimicrobial
activity alone or with equimolar concentrations of
complementary sister peptide against L. lactis
HP and M. luteus. *, wild-type sister peptide
used unless stated otherwise.
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Role of Lanthionines in Lacticin 3147LtnaS2A, LtnaC1S, LtnaC1S/S2C, and LtnaS2T were 2-fold less
active (MIC 2500 nM). Thus, whereas some impacts are consis-
tent, e.g., LtnaC1A-Ltnb is one of the most active combinations
against both targets, there are target-specific differences. More
specifically, LtnaS2A-Ltnb is quite active against L. lactis HP but
is one of the combinations with lesser activity against M. luteus
DSM1790, whereas LtnaS2C-Ltnb and LtnaC1A/S2A-Ltnb are
exceptional by virtue of being the only combinations that are
more active against M. flavus than L. lactis.Antimicrobial Activity of Lacticin 3147 Bridge Variants
Because alanine-scanning mutagenesis has already demon-
strated that the mutagenesis of residues involved in the forma-
tion of the other lacticin 3147 bridges has very detrimental
consequences on bioactivity, the benefits of manipulating these
to the same extent as Ring A was debatable. Of the changes that
could be made, it was anticipated that alterations resulting in the
replacement of Lan bridgeswithmeLans and vice versamight be
best tolerated. The corresponding genetic manipulations were
successfully completed, and following confirmation by colony
mass spectrometry that peptides of correct mass were
produced, the activity of the six resultant strains (Ltna S9T,
Ltna T20S, Ltna T22S, Ltnb S16T, Ltnb T22S, and Ltnb T26S)
was initially assessed by well diffusion assays using cell-free
supernatant. This established that all retained some, albeit
reduced, antimicrobial activity (data not shown). The peptides
were purified, and their specific activities were determined as
broth-based MICs. This revealed that in combination with Ltnb,
both LtnaS9T and LtnaT20S are 30-fold less active than wild-
type Ltna, whereas LtnaT22S is more active than other bridge1154 Chemistry & Biology 17, 1151–1160, October 29, 2010 ª2010 Elsevier Ltd All rights resvariants, being only 8-fold less active
than wild type (Figure 3). The tolerance
at this location is also reflected in nature
in that the related a component of the
plantaricin W two-peptide lantibiotic has
a serine at the location corresponding to
LtnaT22. Of the Ltnb peptides assessed
in combination with Ltna, both LtnbS16T
and LtnbT26S are 15-fold less active
than wild-type Ltnb, and LtnbT22S is
a further 4-fold less active (Figure 3).
The greater consequences of manipu-
lating LtnbT22S were not anticipated
because natural Lan-meLan variation
occurs across the natural b peptides,i.e., Ring D corresponds to a meLan in Smbb/Bhtab, Blib, and
the putative Pnmb, Ring E corresponds to a Lan in SmbAb/
bhtAb, and Ring F corresponds to a Lan in Plwb (see Figure S1
available online). The peptides with Lan and meLan interconver-
sions that are most active against L. lactis HP are LtnaT22S,
LtnbS16T, and LtnbT26S. Both combinations (i.e., LtnaT22S-
LtnbS16T and LtnaT22S-LtnbT26S) resulted in a 64-fold reduc-
tion in activity against L. lactisHP relative to the wild-type combi-
nation (MIC 625 nM), which was 2-fold less than the anticipated
impact (8-fold reduction 3 16-fold reduction = 128-fold reduc-
tion) (Figure 3). MIC assays with the bioengineered peptides, in
combination with an equimolar concentration of the relevant
sister peptide, established that antimicrobial activity was also re-
tained, to at least some extent, against M. luteus DSM1790. It
was noted that LtnaT22A-Ltnb and Ltna-LtnbS16T were the
most active combinations (MIC 625 nM) and that in contrast to
peptides in which Ring A was bioengineered, the consequences
of interconverting Lan-MeLan residues had less dramatic strain-
variable consequences (Figure 3).
Thermotolerance of Lacticin 3147 and Bridge Variants
Although thermotolerance is one of the characteristics frequently
associated with lantibiotics, it has not been definitively demon-
strated that the loss of an individual (me)Lan bridge leads to
increased thermal sensitivity. We assessed the impact of high
temperature (80C for 30 min) on the antimicrobial activity of
Ltna, Ltnb, and a selection of peptides in which bridges were
manipulated or removed, including LtnaC1A, LtnaC1S (the
most active of the Ring A mutants), LtnaC1A/S2A, LtnaT20S,
LtnaT22S, LtnbS16T, and LtnbT26S (representing other bridge
mutants of differing activity), was assessed against L. lactis HPerved
Table 1. Impact of Heat (80C for 30 min) on the Antimicrobial
Activity of Lacticin 3147 Peptides and Bioengineered Derivatives
as Determined by MIC Assay Against L. lactis HP
Lacticin 3147 peptides
MIC Value (nm)
without Heating
MIC Value (nm)
After Heating
WT Ltna + Ltnb 9.8 19.5
aC1A + Ltnb 312.5 1250
aC1S + Ltnb 312.5 1250
aC1A/S2A + Ltnb 2500 >2500
aT20S + Ltnb 312.5 625
aT22S + Ltnb 78 156
Ltna + bS16T 156 312.5
Ltna + bT26S 156 312.5
Table 2. Impact of Heat (80C for 30 min) on the Lacticin 3147
Peptides and Bioengineered Derivatives as Determined by Mass
Spectrometry
Peptide T0 T30
WT Ltna 3305 3305.4, 3323.5
LtnaC1A 3273.5 2533.4, 2632.4
LtnaC1S 3290 2549.4
LtnaC1A/S2A 3275.1 3275.6, 3292.6
LtnaT20S 3291 3291.4, 3308.5
LtnaT22S 3291 3291.8, 3307.9
WT Ltnb 2848 2847.6
LtnbS16T 2861.5 2864.57
LtnbT26S 2834 2838.58
Blank without peptide No peak No peak
Masses of resultant fragments are presented. See also Figure S2.
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Role of Lanthionines in Lacticin 3147(Table 1). It was established that this heat treatment brought
about a 2-fold decrease in the specific activity of the wild-type
combination and of LtnaT20S, LtnaT22S, LtnbS16T, and
LtnbT26S (when combined with the corresponding sister
peptide), whereas aC1A and aC1S exhibited greater sensitivity
in the form of a 4-fold reduction in activity. Heat treatment of
LtnaC1A/S2A, which had limited antimicrobial activity prior to
treatment, reduced activity below the detectable threshold. It
would seem that, whereas replacement of one (me)Lan bridge
with another does not impact on heat resistance, the removal
of a bridge has more severe consequences, thereby providing
the first experimental evidence that Lan bridges contribute to
thermotolerance. Mass spectrometric analysis was also carried
out after heat treatment of the peptides (Figure S2; summarized
in Table 2). This revealed that in many cases, i.e., Ltna, LtnaC1A/
S2A, LtnaT20S, and LtnaT22S, the peptides may be oxidized.
However in the case of the Ltna peptides, which on the basis
of MIC results, are most thermosensitive, i.e., LtnaC1A and
LtnaC1S, the peptides appear to be cleaved. This is indicated
by a 741 dalton reduction in the mass of both peptides, which
is consistent with the loss of the six most C terminally located
residues, raising the intriguing possibility that the N-terminal
Ring A structure protects the C terminus of the peptide from
high temperature-induced cleavage. Cleavage of the LtnaC1A/
S2A peptide is not apparent, which perhaps reflects the fact
that its N terminus more closely resembles that present in the
wild-type peptide. With respect to the Ltnb peptides, the wild-
type form of the peptide was not affected by thermal treatment,
whereas thermal treatment of LtnbS16T and LtnbT26S resulted
in a 3–4 dalton increase in mass, the cause of which is not
known.Impact of Proteases on Lacticin 3147 and Bridge
Variants
Lacticin 3147 is sensitive to a number of proteases, such as a-
chymotrypsin (Gardiner et al., 2007). In this study wild-type
peptides and a selection of bioengineered peptides (LtnaC1A,
LtnaC1S, LtnaC1A/S2A, LtnaT20S, LtnaT22S, LtnbS16T,
LtnbT26S) were exposed over a period of 3 hr to a variety of
different proteases, including pepsin, a-chymotrypsin, pronase,
and proteinase K (100 mg/ml). There was a particular interest in
determining the extent to which the peptides were digested afterChemistry & Biology 17, 1151–11 and 3 hr as assessed by mass spectrometric analysis (Figures
S3–S7; summarized in Table 3). First, the stability of the mutant
peptides in buffer over this period was assessed. Some oxida-
tion of Ltnb (wild-type peptide, LtnbT26S, and, to a lesser extent,
LtnbS16T) was apparent after 3 hr, but no degradation was
evident. Exposure to pepsin revealed that both wild-type Ltna
and Ltnb were quite resistant to the enzyme. and digestion is
not evident after 3 hr. However, it is important to note that di-
gested fragments with poor ionization efficiency can go unde-
tected when MALDI-ToF is employed. At least some of the
LtnbS16T, LtnbT26S, and LtnT22S peptides remain undigested
after this time, whereas undigested LtnaC1A, LtnaC1S, and
LtnaT20S could not be detected. As expected from previous lac-
ticin 3147 studies (Gardiner et al., 2007), a-chymotrypsin had
a dramatic impact on peptide integrity, with all peptides having
been digested after 3 hr. However, it was notable that wild-
type Ltna, Ltnb, and LtnbS16T appear to be less sensitive to
the activity of this protease because the undigested form of
the peptides could still be detected after 1 hr exposure. A similar
pattern was apparent on exposure to pronase, a combined
protease from Streptomyces griseus (contains at least three
proteolytic activities, including an extracellular serine protease),
in that the undigested forms of these peptides remained, to at
least some extent, after 3 hr. Of the remaining peptides LtnaC1A
and C1S were most sensitive, providing the only examples
where undigested peptide could not be detected after 1 hr.
Finally, all peptides were highly sensitive to proteinase K with
the wild-type Ltna peptide and the three Ltnb peptides being de-
tected in their undigested form after 1 hr exposure. When exam-
ined in combination, these studies indicate that Ltnb, despite its
more linear structure, is generally less sensitive to the proteases
employed than Ltna. Of the bioengineered forms of Ltnb,
LtnbS16T exhibited a level of sensitivity that was quite similar
to that of the wild-type form, whereas LtnbT26S wasmore sensi-
tive. Of the Ltna peptides the wild-type peptide was consistently
the most resistant to proteases, followed by LtnaT22S.
LtnaT20S and, to an even greater extent, LtnaC1A/S2A,
LtnaC1A, and C1S were more sensitive to these enzymes.
Thus, it would seem that exchanging Lan and meLan bridges
can, in some instances, lead to increased protease sensitivity,160, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1155
Table 3. Summary of Consequences of Digestion of Ltna, Ltnb, and Derivatives Thereof (10 mM/ml) with Proteases (100 mg/ml) over 1
and 3 hr at 37C as Assessed by Mass Spectrometry
0 hr
No protease Pepsin a-Chymotrypsin
1 hr 3 hr 1 hr 3 hr 1 hr 3 hr
WT Ltna 3305 3305.1,
3321.2
3306.2,
3322.3

3305.2 3305.4 3084.2,
3305.3
2486.1
Ltna C1A 3273.5 3274.8 3274.8,
3291.4

2866.2 1998.4 2489.2 1579
Ltna C1S 3290 3290.3 3289.9,
3305.3

3253.1 2640.2 1625.7,
3025
1578.9
Ltna C1A/S2A 3275.1 3275.1,
3292.1
3276.08,
3292.1
2266.34,
2786.7,
3275.01
1562.2 1657.82,
2111.5
1994.29,
2493.41
Ltna T20S 3291 3291.4 3291.4,
3307.4

2549.4 2124.4,
2549.6
2109.11 1855
Ltna T22S 3291 3291.5 3291.7,
3309
2549.5,
3307.6
2552.4,
3307.4
2124.4 1855.2,
2453.7
WT Ltnb 2848 2847.8 2847.2,
2863.2

2847.5 2847.4 1546,
2847.8
1545.7
Ltnb S16T 2861.5 2861.3 2861.6,
2877.6
2861.2 2861.5 1559.9,
2861.4
1560
Ltnb T26S 2834 2833.8 2835.4,
2851.4

2172.9,
2763.8,
2848.6
2848.6

1545.9,
2511.4
2752.6
1531.9,
1545.9.
0 hr
Pronase Proteinase K
1 hr 3 hr 1 hr 3 hr
WT Ltna 3305 2724.1,
2795.2,
3305.3
2538.3,
2724.4,
3306.8
2724.1,
3209.4,
3306.4
2314.3,
2626.4,
Ltna C1A 3273.5 2596, 2289.8,
2474.9
1993.1,
2438.3,
2907.4
1992.6,
2438.8
Ltna C1S 3290 - - 1993.4,
2438.6,
2907.8
1993.3,
2438.5,
2908.6,
2947.5
Ltna C1A/S2A 3275.1 2146.1,
2273.9,
2308.8,
2436.9
2146.1,
2274.2,
2688.5
1856.9,
1993.3,
2171.9,
2907.3
1993.3,
2174.2,
2657.6,
2907.3
Ltna T20S 3291 2496.9,
3291.2
1990.8,
2248.8,
2376.9
1993.2,
2438.4
1993.1,
2439
Ltna T22S 3291 2381.1,
2527.1,
3308.7
2540.1 2249.9, 2156.5,
WT Ltnb 2848 2847.8 2292.9,
2847.5
1709.1,
1851.2,
2847.9
1709,
1851
Ltnb S16T 2861.5 2275.2,
2861.3
2275.2,
2861.5
1723.2,
1865.3,
2861.5
1722.9,
1865.1
Ltnb T26S 2834 2074.3,
2377.5,
2564.5,
2833.7,
2850.5
2071.8,
2485.3
1708.6,
1851.2,
2438.7
1708.6,
1850.7,
2439,
2834
Masses of resultant fragments are presented. Dominant peak is in bold, and mass corresponding to undigested peptide is underlined (peaks corre-
sponding to those observed in control reactions, i.e., enzyme without peptide, have been excluded). See also Figures S3–S7.
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Role of Lanthionines in Lacticin 3147whereas the peptides in which Ring A of Ltnawas removed were
consistently among the most protease sensitive.
DISCUSSION
Lanthionine bridges are the key distinctive features that differen-
tiate lantibiotics from other antimicrobials. The importance of
these bridges with respect to imposing structure on these
peptides is very evident. However, only one study involving
Pep5 has investigated the role of specific bridges in providing
resistance to proteases (Bierbaum et al., 1996), and no
corresponding thermotolerance studies have taken place. In
this study an extensive mutagenesis of Ring A of the lacticin
3147 Ltna peptide was carried out to determine the impact of
the changes made on the antimicrobial activity of these
peptides. This strategy was prompted by an alanine-scanning
mutagenesis study that previously established that the LtnaC1A
and LtnaS2A mutants both retained significant levels of antimi-
crobial activity. The tolerance of Ltna Ring A to change, together
with its atypical orientation and the fact that it bridges two
adjacent residues, makes it particularly fascinating. In this study
the Ring A mutants LtnaS2T, S2C, C1S, and C1S-S2C and C1A-
S2A were generated. Although analysis of the extended set of
‘‘Ring A’’ mutants established that all peptides retained activity
(reaffirming the nonessential nature of the natural Lan structure),
the potency of the peptides relative to one another differed from
one target to another, indicating that Ring A, and perhaps the
extended N-terminal domain, plays a role in the target specificity
of the peptide. Other notable features included the failure to
introduce new structures at the N terminus (other than a simple
Lan to meLan exchange) and the relatively poor activity of
LtnaS2T. As a result of the negative consequences that were
apparent when other residues involved in (me)Lan formation
were converted to alanine (Cotter et al., 2006), the more subtle
Lan/meLan interconversion strategy was employed at other
locations. There have also been examples of the successful
interconversion of Lan and MeLan bridges, in that in lacticin
481 the engineered peptides T33S (MeLan to Lan, Ring A),
S35T, and S42T (Lan toMeLan; Ring B and C) all retained antimi-
crobial activity (Chatterjee et al., 2006). The production of bioen-
gineered derivatives of the closely related nukacin ISK-1 peptide
in which Lan-MeLan interconversions (or other bridge manipula-
tions) have taken place has also been demonstrated. However,
the impact of these changes on antimicrobial activity is not
known (Shioya et al., 2009). The (me)Lan bridge variants of
lacticin 3147, i.e., LtnaS2T (as noted above), LtnaS9T, LtnaT20S
and LtnaT22S, LtnbS16T, LtnbT22S, and LtnbT26S, all retained
at least some antimicrobial activity. When one focuses on the
bridges that are conserved among other lacticin 3147-like two-
peptide lantibiotics (all except Ltna Ring A), natural variation is,
in general, a strong indicator of howwell Lan-meLan interconver-
sion will be tolerated. For example both Ser and Thr residues are
found at locations corresponding to LtnaT22, LtnbS16, and
LtnbT26, whereas those corresponding to LtnaS9 and LtnaT20
are invariable. LtnbT22S is exceptional in this regard in that,
despite more closely resembling the SmbA and bhtA-b peptides,
this peptide retains unexpectedly low activity against L. lactis
HP. The corresponding bridge is located within a domain of
Ltnb that is proposed to be involved in Ltna-Ltnb synergy (CotterChemistry & Biology 17, 1151–1et al., 2006) and, on the basis of this result, may be more impor-
tant than other adjacent bridges in this regard.
The availability of these various bioengineered peptides facil-
itated an investigation of their relative sensitivities to high
temperature and proteolytic enzymes. The impact of the heat
treatment employed had a similar effect on both wild-type lacti-
cin 3147 peptide and (b-methyl) lanthionine bridge variant
peptides with the exception of the representative Ring A
mutants, aC1A and aC1S, the antimicrobial activity of which
was particularly affected by high temperature treatment.
Although many lantibiotics exhibit a high innate thermotoler-
ance, which has been assumed to be due at least in part to
the (me)Lan bridges, this is the first instance in which it has
been demonstrated that removal of a Lan bridge results in
thermal sensitivity. Mass spectrometry indicates that this
reduced activity is due to the cleavage of the peptide between
E24 and the meLan (Ring C) derived from a C25 in the LtnA1 pro-
peptide. Proteolytic enzyme studies combined with mass
spectrometry revealed that the natural Ltna and Ltnb peptides
were consistently the most resistant to digestion. Of the bioen-
gineered peptides the Ltnb derivatives, and LtnbS16T in partic-
ular, were least susceptible to the activities of the various
enzymes, whereas LtnaT20S and, to a greater extent,
LtnaC1A/S2A, LtnaC1A, and C1S were particularly sensitive.
This sensitivity was also apparent in the form of reduced antimi-
crobial activity after pepsin treatment, which did not alter the
activity of the other peptides. This study provides further
evidence of the benefits of possessing (me)Lan or related cyclic
structures (Cooper et al., 2008) at the N terminus of lantibiotics,
as is the case for the Ltna-like peptides and, indeed, many of the
extended mersacidin-like peptide group. It also reveals the
target-specific consequences of manipulating these residues.
More significantly, it has confirmed the importance of such
structures in providing resistance to proteolytic enzymes and,
for the first time, high temperature and will presumably attract
even greater interest in the use of (me)Lan structures to enhance
the stability of non-lantibiotic compounds.SIGNIFICANCE
This study is focused on the consequences of manipulating
the Lan and meLan bridges of the lacticin 3147 peptides
(Ltna and Ltnb) with respect to antimicrobial activity and
resistance to thermal stress and proteolytic digestion.
These investigations are particularly significant in that,
although often claimed to be important, the actual contribu-
tion of Lan and meLan structures to the stability of lantibiot-
ics has not been the subject of such a detailed study
previously. It is revealed that, whereas the interconversion
of Lan and meLan bridges has varying consequences with
respect to activity and stability, Ltna bridge mutants are
consistently more sensitive to thermal treatment and
proteolytic digestion than natural Ltna. In contrast, their
Ltnb counterparts display a resistance to thermal and
proteolytic cleavage that is comparable with that of natural
Ltnb. Most notably, it is established that, although Ring A
of Ltna is not essential for bioactivity, it does provide protec-
tion against thermal stress and proteolytic digestion,160, October 29, 2010 ª2010 Elsevier Ltd All rights reserved 1157
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could also enhance the stability of non-lantibiotic peptides.
EXPERIMENTAL PROCEDURES
Bacterial Strains, Plasmids, Enzymes, Antibiotics,
and Growth Conditions
Wild-type Lacticin 3147 producer Lactococcus lactis MG1363 pMRC01
(Cotter et al., 2005b; McAuliffe et al., 2000)) and all the bridge variants of Lac-
ticin 3147 and indicator strain L. lactis HPwere grown without aeration at 30C
in M17 broth supplementing with 0.5% glucose. Micrococcus luteus was
grown in Muller Hinton Broth (MHB) at 30C, Escherichia coli EC101 was
grown with aeration at 37C in Luria–Bertani (LB) broth. Antibiotics were
used at the following concentrations: 150 mg/ml erythromycin for E. coli and
5 mg/ml erythromycin; 5 mg/ml chloramphenicol for L. lactis; and tetracycline
10 mg/ml for L. lactis. X-gal (5-bromo-4-chloro-3-indole-b-D-galactopyrano-
side) at a concentration of 50 mg/ml was used. 100mM Tris-HCl-10mM
CaCl2 solution was used to dissolve the enzymes Pepsin, a-Chymotrypsin,
Protease, and Proteinase K (chemicals and enzymes from Sigma-Aldrich,
Ireland). All bacterial strains and plasmids used in this study are presented in
Table S1, and oligonucleotides used in study are presented in Table S2.
Site-Directed Mutagenesis
The QuickChange site-directed mutagenesis system (Stratagene) was em-
ployed to engineer the ltnA1 and A2 genes within the pORI280ltnA1A2
(RepA, LacZ+) vector as described previously by Cotter et al. (2003,
2005b). The QuickChange protocol was followed in all steps, except in one
step where E. coli host, EC101 (RepA+), was used. Transformants were
screened with a colony check PCR, using LtnA1SOED and amutation-specific
primer, which was designed to amplify mutated region. Candidates were
confirmed by DNA sequencing to ensure only mutated change was present
and no other alterations in the gene. The mutated plasmid was then electropo-
rated into competent L. lactisMG1363 pMRC01 pVE6007 (Cotter et al., 2003).
The pVE6007 plasmid is temperature-sensitive RepA+ helper plasmid and
needed because the MG1363, pMRC01, and pORI280 lack the RepA gene.
The mutated pORI280 plasmids were integrated by single crossover with the
LtnA1A2 genes on pMRC01 by growing the cultures initially overnight at
30C (GM17 + Ery), followed by two passages (0.1% inoculum) at 37C.
Because pVE6007 is temperature sensitive, growing at 37C will lead to the
loss of this plasmid and, consequently, pORI280. Only the cells in which
a single crossover happened are Ery resistant and will survive during growth.
The second transfer was streaked out (GM17agar + Xgal + Ery), and colonies
were checked for chloramphenicol sensitivity, which confirms the loss of
pVE6007. Individual colonies were incubated in GM17 at 37C and subcul-
tured continuously (0.1% inoculum). At regular intervals the cultures were
diluted and plated out on pre-warmed GM17-Xgal plates and incubated at
37C to find LacZ colonies. White colonies (LacZ) indicated the loss of
pORI280 and the occurrence of a second homologous recombination event.
These colonies were again checked with check PCR to differentiate between
mutant and wild-type revertants and sequenced to confirm PCR results.
MGpMRaT22S and bS16T were generated through bioengineering of
pDF01, i.e., pCi372-PbacA1A2 (Field et al., 2007). Mutagenesis was per-
formed via PCR with Phusion DNA polymerase using 50 phosphorylated
forward primer and nonphosphorylated reverse primers (Table 2). Amplified
PCR product was then subjected to DpnI treatment for 1 hr at 37C and intro-
duced into E. coli TOP10. The respective plasmid pCI372-Pbac A1A2 was
isolated from overnight culture, and the mutated PbacA1A2 insert was ampli-
fied using pPTPLA1A2For(BglII) and pPTPLA1A2Rev(XbaI), digested with BglII
and XbaI enzymes (Roche) ligated into similarly digested pPTPL and then
cloned into E. coli MC1000. The recombinant plasmids were isolated and,
following DNA sequence-based confirmation that mutagenesis has been
successful, were introduced in to L. lactis MG1363 pOM44.
Antimicrobial Activity Assays
The bioactivity of the mutated peptides was tested by doing well-diffusion
assays with the lacticin 3147 sensitive L. lactis HP as an indicator strain, as
described previously (Ryan et al., 1996). Fifty microliters overnight culture of1158 Chemistry & Biology 17, 1151–1160, October 29, 2010 ª2010 EL. lactis HP was added to 20 ml molten GM17 agar, which was cooled to
50C (106 overnight-grown cells per milliliter), poured into a sterile Petri
dish, and allowed to solidify and dried. Wells, 5.8 mm in diameter, were
made in the solidified agar plates and filled with 50 ml of cell-free supernatant
from overnight cultures of the peptide-producing strains. The plates were then
incubated overnight at 30C, and the zones of inhibition were measured.
Differed antagonism assays were carried out by spotting 2 ml of overnight
culture (2 3 108 CFU/ml) of the producing strain onto GM17 agar plates.
Spotted GM17 plates were incubated at 30C overnight and then plates
were treated with UV irradiation for 30 min, then molten GM17 agar with
1 3 106 CFU/ml of L. lactis HP was overlayed and allowed to solidify and
then incubated at 30C overnight. MIC determinations were performed as
described previously (Cotter et al., 2006) in micro-titer plates. L. lactis HP
was grown in M17 broth plus 0.5% glucose (Oxoid), and M. luteus DSM1790
was grown at 30C in MHB. Serial 2-fold dilutions of the peptides were
made in the growth medium of the indicator strain (GM17 or MHB). Bacteria
were then added to give a final inoculum of 105 CFU/ml in a volume of
0.2 ml. After incubating at 30C for 16 hr (optimum growth conditions for
L. lactis HP and M. luteus), MIC values were taken as the lowest peptide
concentration causing inhibition of visible growth. MIC results given are
mean values of three independent determinations.
Purification and Production of Peptides
Strains from which peptide was purified were grown in modified TY broth.
An overnight culture of the producing strain (inGM17)was inoculated into 1 liter
of modified TY broth (1% inoculum) and grown overnight at 30C. The cells
were harvested by centrifugation at 7000 rpm for 20 min, and the cell pellet
was resuspended in 250ml of 70% propan-2-ol (pH 2.0 adjusted with concen-
trated HCl) and stirred for 4 hr at 4C. The mixture was then centrifuged at
7000 rpm for 20 min; the supernatant was reduced to 60 ml by removing
propan-2-ol by rotary evaporation. A Varian C18 Bond Column 10 g (60 ml
volume) was washed consecutively with 60 ml 100% methanol and 60 ml
water. Then the rotary evaporated sample was loaded on this column, washed
with 120 ml 30% ethanol, and finally peptide eluted in 100 ml 70% 2-propanol
(pH 2.0) and stored at 4C. Twenty milliliter volumes of the 100 ml elute were
reduced to 2 ml by rotary evaporation, and aliquots of 1650 ml were then
applied to a Phenomenex (Phenomenex, Cheshire, UK) C12 reverse-phase
RP-HPLC column (Jupiter 4u Proteo 90 A˚, 250 3 10.0 mm, 4 mm) previously
equilibrated with 25% propan-2-ol, 0.1% trifluoroacetic acid (TFA), which
was repeated until all 100 ml elute was concentrated. The column was subse-
quently developed in a gradient of 30% propan-2-ol containing 0.1% TFA to
60% propan-2-ol containing 0.1% TFA from 4 to 40 min at a flow rate of
1.2 ml/min. The HPLC fractions collected at peaks of the peptide A1 or A2,
after all the HPLC runs the fractions were pooled and rotary evaporated to
reduce the amount of propan-2-ol and then treated with N2 gas and kept
frozen at 80C, these frozen samples were freeze dried to get powder form
of peptide, which will be used for quantified antimicrobial assay and mass
spectrometric analysis of peptide. The purified proteins were subjected to
MALDI-ToF MS analysis (Shimadzu) to check the purity of the peptides.
Cyanylation
Purified freeze-dried lacticin 3147 peptides were dissolved in a reducing buffer
22 ml of 10 mM TCEP (aqueous solution) (Wu, 2008; Wu and Watson, 1998) for
15 min at room temperature and then combined by adding 6 ml of 100 mM
CDAP (made with citrate buffer [pH3.0]) (Wu, 2008; Wu and Watson, 1998)
incubating another 15 min at room temperature.
After cyanylation the reactionmixture was then separated and purified using
RP-HPLC, and HPLC fractions were collected and further analyzed by
combining 1 ml of HPLC fraction with 1 ml of a-CHCA (Wu, 2008) using
MALDI-ToF MS analysis (Shimadzu) to measure the mass of cyanylated
peptides.
Impact of Proteases on (b-methyl) Lanthionine
Bridges/Protease Assay
Stability of wild-type and mutant peptides against proteases was carried out
with RP-HPLC purified peptides as described previously (Gardiner et al.,
2007). Enzymes were dissolved in 100 mM Tris HCl-10 mM CaCl2 at 30
C.
Peptides at 10 mg/ml concentrations were treated with enzymes at 100 mg/mllsevier Ltd All rights reserved
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1 and 3 hr time points as described previously (Cotter et al., 2006). Pepsin,
a-chymotrypsin, pronase, and proteinase K (Sigma-Aldrich, Dublin, Ireland)
dissolved in buffer (100 mM Tris HCl-10 mM CaCl2) at their optimum pH (8, 2,
7.8, 7.0, and 7.5, respectively). Well assay with supernatant after treating
with enzymes andMIC determination with peptides after treatingwith enzymes
at a 1 hr time point were also carried out.
Assessment of the Impact of High Temperature
on Lacticin 3147 Peptides
To assess the impact of high temperature on the lacticin 3147 peptides, and
bioengineered derivatives, the peptides are dissolved at a concentration of
10 mg/ml in 1% 100 mM Tris HCl-10 mM CaCl2 buffer; peptides used for treat-
ment are heated to 80C for 30 min, after which time antimicrobial activity and
mass spectrometric analyses were carried out.
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